Literature DB >> 19039247

The alternatively spliced anti-angiogenic family of VEGF isoforms VEGFxxxb in human kidney development.

Heather S Bevan1, Nynke M S van den Akker, Yan Qiu, Japke A E Polman, Rebecca R Foster, Justin Yem, Ali Nishikawa, Simon C Satchell, Steven J Harper, Adriana C Gittenberger-de Groot, David O Bates.   

Abstract

BACKGROUND/AIM: Vascular endothelial growth factor (VEGF), required for renal development, is generated by alternative splicing of 8 exons to produce two families, pro-angiogenic VEGF(xxx), formed by proximal splicing in exon 8 (exon 8a), and anti-angiogenic VEGF(xxx)b, generated by distal splicing in exon 8 (exon 8b). VEGF(165)b, the first described exon 8b-containing isoform, antagonises VEGF(165) and is anti-angiogenic in vivo.
METHODS: Using VEGF(xxx)b-specific antibodies, we investigated its expression quantitatively and qualitatively in developing kidney, and measured the effect of VEGF(165)b on renal endothelial and epithelial cells.
RESULTS: VEGF(xxx)b formed 45% of total VEGF protein in adult renal cortex, and VEGF(165)b does not increase glomerular endothelial cell permeability, it inhibits migration, and is cytoprotective for podocytes. During renal development, VEGF(xxx)b was expressed in the condensed vesicles of the metanephros, epithelial cells of the comma-shaped bodies, invading endothelial cells and epithelial cells of the S-shaped body, and in the immature podocytes. Expression reduced as the glomerulus matured.
CONCLUSION: These results show that the anti-angiogenic VEGF(xxx)b isoforms are highly expressed in adult and developing renal cortex, and suggest that the VEGF(xxx)b family plays a role in glomerular maturation and podocyte protection by regulating the pro-angiogenic pro-permeability properties of VEGF(xxx) isoforms. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19039247      PMCID: PMC2635558          DOI: 10.1159/000177614

Source DB:  PubMed          Journal:  Nephron Physiol        ISSN: 1660-2137


  44 in total

1.  Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.

Authors:  L G Presta; H Chen; S J O'Connor; V Chisholm; Y G Meng; L Krummen; M Winkler; N Ferrara
Journal:  Cancer Res       Date:  1997-10-15       Impact factor: 12.701

2.  Vascular endothelial growth factor mRNA expression in minimal change, membranous, and diabetic nephropathy demonstrated by non-isotopic in situ hybridisation.

Authors:  E Bailey; M J Bottomley; S Westwell; J H Pringle; P N Furness; J Feehally; P E Brenchley; S J Harper
Journal:  J Clin Pathol       Date:  1999-10       Impact factor: 3.411

3.  VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression.

Authors:  Jeanette Woolard; Wen-Ying Wang; Heather S Bevan; Yan Qiu; Lucia Morbidelli; Rowan O Pritchard-Jones; Tai-Gen Cui; Marto Sugiono; Elizabeth Waine; Rachel Perrin; Rebecca Foster; Jonathon Digby-Bell; Jacqueline D Shields; Cheryl E Whittles; Rosey E Mushens; David A Gillatt; Marina Ziche; Steven J Harper; David O Bates
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

4.  Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases.

Authors:  Vera Eremina; Manish Sood; Jody Haigh; András Nagy; Ginette Lajoie; Napoleone Ferrara; Hans-Peter Gerber; Yamato Kikkawa; Jeffrey H Miner; Susan E Quaggin
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

5.  VEGF-Trap: a VEGF blocker with potent antitumor effects.

Authors:  Jocelyn Holash; Sam Davis; Nick Papadopoulos; Susan D Croll; Lillian Ho; Michelle Russell; Patricia Boland; Ray Leidich; Donna Hylton; Elena Burova; Ella Ioffe; Tammy Huang; Czeslaw Radziejewski; Kevin Bailey; James P Fandl; Tom Daly; Stanley J Wiegand; George D Yancopoulos; John S Rudge
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

6.  Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocytes.

Authors:  Rebecca R Foster; Moin A Saleem; Peter W Mathieson; David O Bates; Steven J Harper
Journal:  Am J Physiol Renal Physiol       Date:  2004-08-31

7.  Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties.

Authors:  Simon C Satchell; Karen L Anderson; Peter W Mathieson
Journal:  J Am Soc Nephrol       Date:  2004-03       Impact factor: 10.121

8.  Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation.

Authors:  G Breier; U Albrecht; S Sterrer; W Risau
Journal:  Development       Date:  1992-02       Impact factor: 6.868

9.  VEGF is required for growth and survival in neonatal mice.

Authors:  H P Gerber; K J Hillan; A M Ryan; J Kowalski; G A Keller; L Rangell; B D Wright; F Radtke; M Aguet; N Ferrara
Journal:  Development       Date:  1999-03       Impact factor: 6.868

10.  VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy.

Authors:  A H R Varey; E S Rennel; Y Qiu; H S Bevan; R M Perrin; S Raffy; A R Dixon; C Paraskeva; O Zaccheo; A B Hassan; S J Harper; D O Bates
Journal:  Br J Cancer       Date:  2008-03-18       Impact factor: 7.640

View more
  39 in total

1.  VEGFA family isoforms regulate spermatogonial stem cell homeostasis in vivo.

Authors:  Kyle C Caires; Jeanene M de Avila; Andrea S Cupp; Derek J McLean
Journal:  Endocrinology       Date:  2011-12-06       Impact factor: 4.736

Review 2.  VEGFA splicing: divergent isoforms regulate spermatogonial stem cell maintenance.

Authors:  Kevin M Sargent; Debra T Clopton; Ningxia Lu; William E Pohlmeier; Andrea S Cupp
Journal:  Cell Tissue Res       Date:  2015-11-09       Impact factor: 5.249

3.  WT1-dependent sulfatase expression maintains the normal glomerular filtration barrier.

Authors:  Valérie A Schumacher; Ursula Schlötzer-Schrehardt; S Ananth Karumanchi; Xiaofeng Shi; Joseph Zaia; Stefanie Jeruschke; Dongsheng Zhang; Hermann Pavenstädt; Hermann Pavenstaedt; Astrid Drenckhan; Kerstin Amann; Carrie Ng; Sunny Hartwig; Kar-Hui Ng; Jacqueline Ho; Jordan A Kreidberg; Mary Taglienti; Brigitte Royer-Pokora; Xingbin Ai
Journal:  J Am Soc Nephrol       Date:  2011-06-30       Impact factor: 10.121

Review 4.  Unwrapping the origins and roles of the renal endothelium.

Authors:  Donna Beer Stolz; Sunder Sims-Lucas
Journal:  Pediatr Nephrol       Date:  2014-03-15       Impact factor: 3.714

5.  Post-transcriptional regulation in cancer progression : Microenvironmental control of alternative splicing and translation.

Authors:  Michael Jewer; Scott D Findlay; Lynne-Marie Postovit
Journal:  J Cell Commun Signal       Date:  2012-10-09       Impact factor: 5.782

6.  Effects of exogenous VEGF(165)b on invasion and migration of human lung adenocarcinoma A549 cells.

Authors:  Jing Chen; Zhenyu Li; Sheng Zhang; Ruiguang Zhang; Meera Dassarath; Gang Wu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-10-25

7.  Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling.

Authors:  Karen Sison; Vera Eremina; Hans Baelde; Wang Min; Masanori Hirashima; I George Fantus; Susan E Quaggin
Journal:  J Am Soc Nephrol       Date:  2010-08-05       Impact factor: 10.121

Review 8.  Therapeutic potential of manipulating VEGF splice isoforms in oncology.

Authors:  Emma S Rennel; Steven J Harper; David O Bates
Journal:  Future Oncol       Date:  2009-06       Impact factor: 3.404

9.  VEGF in the lung: a role for novel isoforms.

Authors:  Julia Varet; Samantha K Douglas; Laura Gilmartin; Andrew R L Medford; David O Bates; Steven J Harper; Ann B Millar
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-03-12       Impact factor: 5.464

Review 10.  The role of VEGF 165b in pathophysiology.

Authors:  Maria Peiris-Pagès
Journal:  Cell Adh Migr       Date:  2012-10-17       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.